(Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced updates to the Phase 3 ...

Breast cancer is a complex disease with many types. Understanding the specific type and classification of the breast cancer you have is crucial so that you can fully participate as an informed partner ...

Giredestrant plus everolimus does not increase treatment burden in advanced breast cancer, new safety and patient-reported outcome data from the evERA BC trial show.

Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER ...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient ...

The highest rates of HER2 positivity were observed in bladder cancer, uterine serous carcinoma, and esophagogastric junction cancer. New research suggests the incidence of HER2 positivity is low ...

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent Kinase ...

If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...